![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JM Soleilhac, E Lucas, A Beaumont, S Turcaud, JB Michel, D Ficheux, MC Fournie- Zaluski and BP Roques
Departement de Chimie Organique, INSERM U266, CNRS UA498, Paris, France.
Neutral endopeptidase 24.11 (EC 3.4.24.11) inactivates atrial natriuretic peptide by cleaving the hormone between Cys7 and Phe8, and inhibitors of the enzyme have consequent natriuretic and diuretic properties. The in vivo sites of degradation of this peptide by the zinc-metallopeptidase, however, remain to be established. Because an endopeptidase-24.11-like activity has recently been reported in the rat mesenteric artery, we have further investigated the degradation of atrial natriuretic peptide in vascular tissue. Endopeptidase-24.11 activity was detected in solubilized membrane preparations from rat and rabbit vascular tissue, using [3H]D-Ala2-leucine enkephalin as substrate, and both rabbit and rat aorta preparations were also found to cleave atrial natriuretic peptide between Cys7 and Phe8. In both cases, hydrolysis was inhibited by neutral endopeptidase inhibitors, with Ki values close to their Ki values for the pure enzyme. In preparations of rabbit aorta denuded of endothelium by saponin treatment, the hydrolysis of the Gly3-Phe4 bond of [3H]D-Ala2-leucine enkephalin and the Cys7-Phe8 bond of atrial natriuretic peptide was reduced by greater than 90%. The high performance liquid chromatography method used to follow the degradation of atrial natriuretic peptide differed from previously published procedures, in that samples to be injected were first treated with excess dithiothreitol to reduce the Cys7-Cys23 disulfide bridge. This facilitated the separation of the intact peptide and its metabolites. The presence of the 94-kDa neutral endopeptidase in rabbit aortic tissue was definitively established using a new potent 125I-labeled inhibitor, [125I]RB104 [2-[(3- [125I]iodo-4-hydroxy)phenylmethyl]-4-N-[3- hydroxyamino-3-oxo-1- phenylmethyl propyl]amino-4-oxobutanoic acid] (Ki, 30 pM), which selectively labeled the enzyme after sodium dodecyl sulfate- polyacrylamide gel electrophoresis of the membrane preparations. Therefore, despite its low concentrations in the vasculature, the presence of endopeptidase-24.11 almost exclusively in endothelial tissue suggests that the enzyme is ideally localized to inactivate circulating atrial natriuretic peptide.
This article has been cited by other articles:
|
|
 |
|
  M. N. Barber, M. Kanagasundaram, C. R. Anderson, L. M. Burrell, and R. L. Woods Vascular neutral endopeptidase inhibition improves endothelial function and reduces intimal hyperplasia Cardiovasc Res, July 1, 2006; 71(1): 179 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Kalra, J. R. Clague, A. P. Bolger, S. D. Anker, P. A. Poole-Wilson, A. D. Struthers, and A. J. Coats Myocardial Production of C-Type Natriuretic Peptide in Chronic Heart Failure Circulation, February 4, 2003; 107(4): 571 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R Kalra, S. D Anker, and A. J.S Coats Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin Cardiovasc Res, August 15, 2001; 51(3): 495 - 509. [Full Text] [PDF]
|
|
|
|
 |
|
 P.R Kalra, S.D Anker, A.D Struthers, and A.J.S Coats The role of C-type natriuretic peptide in cardiovascular medicine Eur. Heart J., June 2, 2001; 22(12): 997 - 1007. [PDF]
|
|
|
|
 |
|
 J. Dai, R. Shen, M. Sumitomo, J. S. Goldberg, Y. Geng, D. Navarro, S. Xu, J. A. Koutcher, M. Garzotto, C. T. Powell, et al. Tumor-Suppressive Effects of Neutral Endopeptidase in Androgen-independent Prostate Cancer Cells Clin. Cancer Res., May 1, 2001; 7(5): 1370 - 1377. [Abstract] [Full Text]
|
|
|
|
|
|
K. E. Loke, S. K. Laycock, S. Mital, M. S. Wolin, R. Bernstein, M. Oz, L. Addonizio, G. Kaley, and T. H. Hintze Nitric Oxide Modulates Mitochondrial Respiration in Failing Human Heart Circulation, September 21, 1999; 100(12): 1291 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, F. A. Recchia, R. Bernstein, X. Xu, A. Nasjletti, and T. H. Hintze Kinin-Mediated Coronary Nitric Oxide Production Contributes to the Therapeutic Action of Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibitors and Amlodipine in the Treatment in Heart Failure J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 742 - 751. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Kugiyama, S. Sugiyama, T. Matsumura, Y. Ohta, H. Doi, and H. Yasue Suppression of Atherosclerotic Changes in Cholesterol-Fed Rabbits Treated With an Oral Inhibitor of Neutral Endopeptidase 24.11 (EC 3.4.24.11) Arterioscler. Thromb. Vasc. Biol., August 1, 1996; 16(8): 1080 - 1087. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Li, R. M. Booze, and L. B. Hersh Tissue-specific Expression of Rat Neutral Endopeptidase (Neprilysin) mRNAs J. Biol. Chem., March 17, 1995; 270(11): 5723 - 5728. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
